SEARCH

SEARCH BY CITATION

Appendix e-1a. Mission statement of QSS.

Appendix e-1b. Mission statement of TTA.

Appendix e-2. Conflict of interest statement.

Appendix e-3a. Quality Standards Subcommittee (QSS) members.

Appendix e-3b. Therapeutics and technology assessment subcommittee members.

Appendix e-4a. Classification of evidence for therapeutic intervention.

Appendix e-4b. Classification of evidence for rating of a prognostic article.

Appendix e-5. Classification of recommendations.

Table e-1. Folate in the reduction of birth defects in WWE.

Table e-2. Hemorrhagic complications with AED Exposure.

Table e-3. Placental and breast milk transfer and evidence for symptomatic effects.

Table e-4. Pharmacokinetics of lamotrigine during Pregnancy.

Table e-5. Pharmacokinetics of carbamazepine during Pregnancy.

Table e-6. Pharmacokinetics of phenytoin during Pregnancy.

Table e-7. Pharmacokinetics of oxcarbazepine during Pregnancy.

Table e-8. Pharmacokinetics of valproic acid, primidone, ethosuximide, and levetiracetam during pregnancy.

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

FilenameFormatSizeDescription
EPI_2130_sm_11209_E-Tables.doc111KSupporting info item
EPI_2130_sm_E-appendices-FolicAcidVitK.doc33KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.